{"name":"SOLASCURE LIMITED","company_number":"10826246","status":"Active","type":"Private Limited Company","incorporated":"2017-06-20","dissolved":null,"registered_office":"Wellington House, East Road, Cambridge, England, CB1 1BH","postcode":"CB1 1BH","sic_codes":[{"code":72110,"description":"Research and experimental development on biotechnology"}],"principal_activity":"The principal activity of the Company during the financial year was developing wound care products that significantly improve the health and wellbeing of patients with chronic wounds.","previous_names":[{"name":"AURASE LIMITED","changed_on":"2018-02-13"}],"warnings":[],"accounts":{"category":"Total Exemption Full","year_end":"30 June","last_made_up_to":"2026-06-30","next_due":"2028-03-31"},"employees":{"count":9,"accounts_date":"2026-06-30"},"financials":[{"financial_date":"2026-06-30","net_assets":3510755,"cash":113155,"average_employees":9},{"financial_date":"2025-06-30","net_assets":4196154,"cash":810344,"average_employees":10},{"financial_date":"2024-06-30","net_assets":4859496,"cash":837912,"average_employees":11},{"financial_date":"2023-06-30","net_assets":6536098,"cash":1865511},{"financial_date":"2022-06-30","net_assets":5885142,"cash":970333}],"officers":{"current":9,"resigned":7,"complete":true,"note":"Names and details of individual officers are on the People page (subscriber-only on this site) and free at Companies House."},"charges":{"total":0,"outstanding":0},"gazette_notices":[],"insolvency_outcome":null,"ai_summary":"SolasCure Limited occupies a strategically attractive position in the growing chronic wound care market, underpinned by a £3.5M patent portfolio and Cambridge-based R&D capabilities, but faces an existential cash constraint with only £810K remaining and £22.7M in accumulated losses. The next 12-18 months represent a critical window: the company must secure non-dilutive funding through grants and licensing partnerships, or raise additional capital, to bridge the gap between current burn and commercial revenue. Success hinges on executing a capital-efficient path to regulatory milestones that unlock partnership value before liquidity pressures force suboptimal decisions.","website":"https://www.solascure.com","links":{"page":"https://www.companiesintheuk.co.uk/ltd/solascure","people":"https://www.companiesintheuk.co.uk/company/solascure/people","filing_history":"https://www.companiesintheuk.co.uk/company/solascure/filing-history","companies_house":"https://find-and-update.company-information.service.gov.uk/company/10826246","financials":"https://www.companiesintheuk.co.uk/company/solascure/financial","control":"https://www.companiesintheuk.co.uk/company/solascure/control","ai_analysis":"https://www.companiesintheuk.co.uk/company/solascure/analysis"},"source":"CompaniesInTheUK, from Companies House, The Gazette and other public registers (see /support/about). Cite as: CompaniesInTheUK, https://www.companiesintheuk.co.uk/ltd/solascure"}